© Reuters. The company logo for Johnson & Johnson is displayed on the screen to celebrate the 75th anniversary of the company’s NYSE listing in New York.
By Reuters Staff
(Reuters) – The US Food and Drug Administration (FDA) said it discovered problems including paint peeling and debris during an inspection at a US factory in Baltimore where the COVID-19 vaccine was made by Johnson & Johnson (NYSE 🙂 and asked to correct the problem.
The plant management companies have sought regulatory permission to produce J&J vaccines there. It stopped production at the factory recently, saying that the FDA asked it to do so after testing.
The FDA says its tests are complete and in a report detailing a long list of problems to overcome, including not training staff to avoid cross-contamination of COVID-19’s Johnson & Johnson and AstraZeneca (NASDAQ :), have also been done at the site. Production of that vaccine, which has not yet been approved in the United States, has also been discontinued.
Inspection, conducted between April 12 and April 20, revealed that the building was not of the right size or design to facilitate cleaning, maintenance or proper operation.
It describes the wall as having a brown substance on it. The FDA also says the equipment used is not sized appropriately for cleaning and maintenance.
Johnson & Johnson said they will exercise their oversight to ensure that all regulatory observations are promptly and comprehensively addressed. (https: //
Emerged not immediately available for comment.
No vaccine produced at this plant has been distributed for use in the United States.
Fusion Media or anyone associated with Fusion Media will not be liable in any way for loss or damage resulting from dependence on information including data, quotes, charts and buy / sell signals contained in the this site. Please be fully informed about the risks and costs associated with trading the financial markets, which is one of the riskiest investments possible.